What should it take to describe a substance or product as “sperm‐safe”

dc.contributor.authorMortimer, David
dc.contributor.authorBarratt, Christopher L.R.
dc.contributor.authorBjörndahl, Lars
dc.contributor.authorDe Jager, Christiaan
dc.contributor.authorJequier, Anne M.
dc.contributor.authorMuller, Charles H.
dc.date.accessioned2013-04-19T08:55:55Z
dc.date.available2014-01-30T00:20:03Z
dc.date.issued2013
dc.description.abstractBACKGROUND: Male reproductive potential continues to be adversely affected by many environmental, industrial and pharmaceutical toxins. Pre‐emptive testing for reproductive toxicological (side‐)effects remains limited, or even non‐existent. Many products that come into direct contact with spermatozoa lack adequate testing for the absence of adverse effects, and numerous products that are intended for exposure to spermatozoa have only a general assumption of safety based on the absence of evidence of actual harm. Such assumptions can have unfortunate adverse impacts on at‐risk individuals (e.g. couples who are trying to conceive), illustrating a clear need for appropriate up‐front testing to establish actual “sperm safety”. METHODS: After compiling a list of general areas within the review’s scope relevant literature and other information was obtained from the authors’ personal professional libraries and archives, and supplemented as necessary using PubMed and Google searches. Review by co‐authors identified and eliminated errors of omission or bias. RESULTS: This review provides an overview of the broad range of substances, materials and products that can affect male fertility, especially through sperm fertilizing ability, along with a discussion of practical methods and bioassays for their evaluation. It is concluded that products can only be claimed to be “sperm‐safe” after performing objective, properly designed experimental studies; extrapolation from supposed predicate products or other assumptions cannot be trusted. CONCLUSIONS: We call for adopting the precautionary principle, especially when exposure to a product might affect not only a couple’s fertility potential but also the health of resulting offspring and perhaps future generations.en_US
dc.description.librarianhb2013en_US
dc.description.urihttp://www-humupd.oxfordjournals.org.en_US
dc.identifier.citationMortimer, D, Barratt, CLR, Björndahl, L, De Jager, C, Jequier, AM & Muller, CH 2013, 'What should it take to describe a substance or product as “sperm‐safe”, Human Reproduction Update, vol.19, supplement 1, pp. i1–i48en_US
dc.identifier.issn1355-4786 (print)
dc.identifier.issn1460-2369 (online)
dc.identifier.other10.1093/humupd/dmt008
dc.identifier.urihttp://hdl.handle.net/2263/21332
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.rights© The Author 2013. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Human Reproduction Update. following peer review. The definitive publisher-authenticated version Human Reproduction Update, Vol.19, Supplement 1 pp. i1–i48, 2013 is available online at : http://www-humupd.oxfordjournals.orgen_US
dc.subjectSpermatozoaen_US
dc.subjectToxicityen_US
dc.subjectSafetyen_US
dc.subjectMale fertilityen_US
dc.subjectPharmacologyen_US
dc.titleWhat should it take to describe a substance or product as “sperm‐safe”en_US
dc.typePostprint Articleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Mortimer_What(2013).pdf
Size:
1.05 MB
Format:
Adobe Portable Document Format
Description:
Postprint Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: